EXPLORE THE SCIENCE
TL;DR: A 2026 preprint in medRxiv warned that a standard Alzheimer’s disease biomarker-clock analysis can create a countdown paradox, where later biomarker-clock ages appear linked to faster mild cognitive impairment onset because of the way remaining time is…
Read article
TL;DR: A 2026 preprint in medRxiv found that brain-derived p-tau217%, a blood marker designed to isolate central nervous system tau, classified Alzheimer disease pathology better than standard plasma p-tau217 in several Alzheimer cohorts. Key Findings CNS-sele…
Read article
TL;DR: A 2026 medRxiv preprint applied the AT(N) framework, an Alzheimer’s disease biomarker system for amyloid, tau, and neurodegeneration, to 84 older adults with focal epilepsy and found that only 32.1% had normal blood biomarkers, while early-onset epileps…
Read article
TL;DR: A 2026 study in Translational Psychiatry found that three different plasma p-tau217 assays separated Alzheimer’s dementia from controls and frontotemporal degeneration with excellent accuracy, shifting the test from whether the marker works to which pla…
Read article
TL;DR: A 2026 study in Nature Communications found that self-administered finger-prick blood tests for phosphorylated tau 217 (p-tau217), an Alzheimer’s tau marker, and glial fibrillary acidic protein (GFAP), an astrocyte-injury marker, correlated with cogniti…
Read article